Molbio Diagnostics IPO 2026
Molbio Diagnostics Limited is launching its Mainboard IPO to raise capital through a combination of fresh issue and offer for sale. The company operates in molecular diagnostics and point-of-care testing solutions.
IPO Open Date
10 Aug 2026IPO Close Date
12 Aug 2026Price Band
₹768 – ₹807Lot Size
18 SharesIssue Size
₹939.70 CrFresh Issue
₹200 CrOFS
₹739.70 CrFace Value
₹1Molbio Diagnostics IPO Details
| Particulars | Details |
|---|---|
| Company Name | Molbio Diagnostics Limited |
| IPO Type | Mainboard IPO |
| Issue Type | Book Built Issue |
| IPO Open Date | 10 August 2026 |
| IPO Close Date | 12 August 2026 |
| Price Band | ₹768 – ₹807 per share |
| Face Value | ₹1 per share |
| Issue Size | Approximately ₹939.70 Crore |
| Fresh Issue | ₹200 Crore |
| Offer for Sale | Approximately ₹739.70 Crore |
| Lot Size | 18 Shares |
| Minimum Investment | ₹14,526 at upper price band |
| Listing | BSE & NSE |
| IPO Status | Upcoming |
Molbio Diagnostics IPO Timeline
*Timeline should be verified against the final exchange and registrar schedule.
Molbio Diagnostics Company Profile
Molbio Diagnostics Limited is a molecular diagnostics company focused on developing and manufacturing point-of-care diagnostic solutions. The company is known for its Truenat platform, a portable real-time PCR-based molecular diagnostic system.
Its diagnostic solutions are designed to enable testing closer to the patient and can be used for detection of multiple infectious diseases. The company serves healthcare institutions, government programmes, laboratories and other healthcare customers.
Molecular Diagnostics, Point-of-Care Testing, PCR-Based Diagnostic Solutions, Infectious Disease Testing and Healthcare Diagnostics.
Molbio Diagnostics – Key Products & Solutions
Truenat Platform
Truenat is Molbio's portable, battery-operated real-time PCR platform designed for molecular testing at the point of care.
Diagnostic Tests
- Tuberculosis Testing
- COVID-19 Testing
- Influenza Testing
- Dengue Testing
- Malaria Testing
- Hepatitis Testing
- Other Infectious Disease Tests
Molbio Diagnostics Business Model
Molbio Diagnostics operates in the molecular diagnostics market and generates revenue through diagnostic instruments, consumables and related testing solutions.
- Point-of-Care Molecular Diagnostics
- Real-Time PCR Technology
- Diagnostic Instruments
- Diagnostic Test Kits
- Healthcare & Laboratory Solutions
Molbio Diagnostics Financial Performance
The company has reported strong growth in revenue and profitability over the recent financial years.
| Financial Year | Revenue / Income | Profit After Tax |
|---|---|---|
| FY 2023-24 | ₹840.6 Crore* | ₹83.5 Crore* |
| FY 2024-25 | ₹1,028 Crore* | ₹138.6 Crore* |
| FY 2025-26 | ₹1,445.69 Crore* | ₹164.14 Crore* |
*Figures are presented in rounded form based on publicly reported IPO financial information. Refer to the final RHP for audited figures, restatements and accounting definitions.
Molbio Diagnostics IPO – Objects of the Issue
The fresh issue proceeds are proposed to be used for purposes specified in the company's offer documents, including funding business and capital requirements and other general corporate purposes.
The OFS component represents shares being sold by existing shareholders. The proceeds from the OFS generally go to the selling shareholders and do not constitute fresh capital raised by Molbio Diagnostics.
Molbio Diagnostics Promoters & Investors
Molbio Diagnostics has received backing from prominent institutional investors. The company has been associated with Temasek-backed investment and institutional ownership.
The company's institutional backing and established diagnostics platform are among the key points investors may consider while evaluating the IPO.
Molbio Diagnostics IPO – Strengths & Risks
Potential Strengths
- ✔ Established molecular diagnostics platform
- ✔ Truenat point-of-care technology
- ✔ Presence in infectious disease diagnostics
- ✔ Strong revenue growth
- ✔ Improving profitability
- ✔ Institutional investor backing
- ✔ Growing demand for point-of-care diagnostics
Key Risks
- ⚠ Healthcare diagnostics is highly competitive
- ⚠ Regulatory approvals may impact products
- ⚠ Dependence on healthcare and diagnostic demand
- ⚠ Technology and product development risks
- ⚠ Large OFS component
- ⚠ IPO valuation risk
- ⚠ Equity markets can remain volatile
Molbio Diagnostics IPO GMP
Grey Market Premium (GMP) is an unofficial indicator of market sentiment and is not regulated or guaranteed by stock exchanges or SEBI.
Molbio Diagnostics IPO Allotment Status
After the IPO closes, investors can check the allotment status through the IPO registrar using PAN, application number or other required details.
| Allotment Information | Status |
|---|---|
| IPO Open | 10 August 2026 |
| IPO Close | 12 August 2026 |
| Basis of Allotment | Expected after IPO closing* |
| Refund | As per final IPO schedule* |
| Share Credit | As per final IPO schedule* |
| Listing | Expected after allotment* |
